BL0175

DRUG3 trials

Sponsors

Shanghai Best-Link Bioscience, LLC

Conditions

Breast CancerBreast Cancer (Locally Advanced or Metastatic)Endometrial CancerOvarian CancerPostmenopausal Women

Phase 1

A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer

RecruitingNCT06738966

Shanghai Best-Link Bioscience, LLCBreast Cancer, Endometrial Cancer, Ovarian Cancer

Start: 2025-03-10End: 2027-12-26Target: 9Updated: 2026-01-13

A Study of Single Dose of BL0175 in Postmenopausal Women

Not yet recruitingNCT07366632

Shanghai Best-Link Bioscience, LLCPostmenopausal Women

Start: 2026-01-26End: 2026-12-21Target: 27Updated: 2026-01-26

Phase 2

A Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer

Not yet recruitingNCT07658183

Shanghai Best-Link Bioscience, LLCBreast Cancer (Locally Advanced or Metastatic)

Start: 2026-07-20End: 2028-05-31Target: 120Updated: 2026-06-18

Related Papers

BL0175, a novel nano-mediated polypeptide conjugate of protein degrader, in patients (pts) with locally advanced/metastatic HR+/HER2− breast cancer (HR+, HER2- LA/mBC): Initial results from a phase 1 study.

Journal of Clinical Oncology2026-05-27